Ascendis Pharma A/SASNDNASDAQ
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank29
3Y CAGR-49.8%
5Y CAGR-55.4%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-49.8%/yr
vs -8.8%/yr prior
5Y CAGR
-55.4%/yr
Recent acceleration
Acceleration
-40.9pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0x
Contraction
Streak
5 yr
Consecutive declineCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 16.27 | -26.0% |
| 2024 | 21.98 | -13.3% |
| 2023 | 25.36 | -80.2% |
| 2022 | 128.35 | -84.0% |
| 2021 | 802.71 | -13.0% |
| 2020 | 922.56 | +136.9% |
| 2019 | 389.37 | +109.5% |
| 2018 | 185.87 | -69.1% |
| 2017 | 600.96 | +738.2% |
| 2016 | 71.70 | - |